October 2026 Webinar

Marc Rothenberg

Marc Rothenberg is the Director of Allergy and Immunology at Cincinnati Children's Hospital Medical Center, a Professor at the University of Cincinnati College of Medicine, the Founder and Director of the Cincinnati Center for Eosinophilic Disorders, the Founder and Director of the NIH’s Consortium of Eosinophilic Gastrointestinal Disease Researchers and the incumbent of the Bunning Chair of Allergy and Immunology. He has published over 500 peer review articles that have garnered >50,000 citations, an H-index of >130, and laid the foundation for therapeutics that are advancing the allergy/immunology field including the first drug approval by the FDA for eosinophilic esophagitis. He is a member of the National Academy of Medicine. He is the past President of the International Eosinophil Society (IES).

Michael Wechsler

Michael E. Wechsler is Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at NJH in Denver, Director of the National Jewish Health (NJH)/Cohen Family Asthma Institute and Associate Vice President for Innovation and Industry Relations at NJH. In addition to clinical work in pulmonary & critical care medicine, Professor Wechsler’s research focuses on clinical and translational asthma with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (i.e. Churg-Strauss Syndrome, CSS). He has led studies focusing on novel biologic agents for asthma and related diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, and tezepelumab. He has published more than 250 peer-reviewed manuscripts relating to asthma, EGPA and eosinophilic lung diseases. He was a member of the Steering Committee and site Principal Investigator of the NIH-sponsored Asthma Clinical Research Network (ACRN, now called AsthmaNet), a multicentre asthma clinical trials consortium, and currently serves as the PI of the Denver site of the Precision Intervention in Severe/Exacerbating Asthma (PRECISE) network. A member of the American Society of Clinical Investigation and the Association of American Physicians, he has participated in many different task forces related to the study of eosinophilic lung diseases that were sponsored by the NIH, the FDA, the European Respiratory Society and the International Eosinophil Society. He is currently Associate Editor of the journal Chest and has served as Associate Editor of the journal Allergy and on the editorial board of the European Journal of Clinical Investigation.

Dr. Wechsler received AB and MMSc degrees from Harvard University in Boston and an MD degree from McGill University in Montreal. He completed medical training at Beth Israel Hospital in Boston, and as part of the Harvard Combined Pulmonary and Critical Care Fellowship Training Program.

Calies Menard-Katcher

Erin Foster

Dr. Erin Foster is a board-certified dermatologist with a special interest in complex skin disorders, blistering diseases, and mucosal dermatology. She is a fellow of the American Academy of Dermatology and the International Society for the Study of Vulvovaginal Disease, and a member of the Women’s Dermatology Society and Medical Dermatology Society. She is a past board member of the Vulvar Dermatoses Research Consortium. 

Dr. Foster received her PhD in skin immunology in 2010 from Oregon Health & Science University and her MD in 2016 from the University of Texas Health Science Center at San Antonio. Her research is focused on shared decision making between patients and clinicians, mucosal dermatology, and women’s health. When she isn't working, she is hiking, reading, napping, or cheering at her kids' games and activities.